9141 Fox Bridge Drive
Sunset Hills, MO 63127
Hemavist is a lipid formulation of a novel gadolinium contrast agent for magnetic resonance imaging, designed for normal 1H MRI enhancement. Current 1H contrast agents are rapidly cleared from the circulatory system, and are generally limited to the imaging of blood/brain barrier disruptions. Hemavist's high relaxivity and persistence in the bloodstream lowers the effective imaging dose by an order of magnitude relative to its chief competitor, Magnevist®. More importantly, its persistence in the bloodstream opens a new pathway to angiographic evaluation of cerebral and cardiac perfusion.
These rodent images show Hemavist's impact on blood flow imaging in a study performed by Dr. Tom Brady at Massachusetts General Hospital. Conventional MRI shows no vascular detail. Hemavist clearly images the lower descending aorta and its branches in the abdominal region, as well as the carotids and pulmonary areteries in the thoracic cavity.
Like other lipid emulsions, Hemavist is removed from the circulation by the cells of the reticuloendothelial system, and is deposited in the liver prior to excretion. Thus, 24 hours after infusion, it is a useful agent for the early detection of hepatic tumors
Rodent studies demonstrate the quantitative elimination of Hemavist .
Hemavist's safety profile is excellent. All treatment animals survived 1, 2, 4, 8, and 16 times the clinical dose administered on each of 28 consecutive days totals of 28, 56, 112, 224, and 448 times the intended single dosage! Gross and microscopic pathology, serum enzymes and organ weights were normal in the 28, 56 and 112x groups. The only anomalies observed in the 224 and 448x groups were mild enlargement and discoloration of the liver. The outstanding safety and efficacy profiles of Hemavist make it a prime candidate for clinical evaluation as a blood pool and hepatic imaging agent
Copyright ChemVantage Consultants, LLC